Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
July 06 2023 - 7:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced that it will host a virtual Key Opinion
Leader (KOL) webinar on Tuesday, July 11, 2023, at 4:30 p.m. EDT to
review additional data from its exploratory Phase 2b RESPOND
clinical study of Sildenafil Cream, 3.6% in women with female
sexual arousal disorder (FSAD). In addition to the data
presentation, the webinar will include discussions on the diagnosis
and treatment of FSAD, the unmet medical need among women and the
market opportunity for a pharmacologic treatment for FSAD. Daré and
its collaborator, Strategic Science & Technologies, LLC, a
Cambridge, MA based novel topical drug delivery company, previously
announced positive topline data from the study.
Sabrina Martucci Johnson, President and CEO of
Daré Bioscience, will host the webinar and will be joined by:
- Sheryl A. Kingsberg, PhD, Division
Chief of Behavioral Medicine, Department of OBGYN, University
Hospitals Cleveland Medical Center, Ohio, and Past President of The
International Society for the Study of Women's Sexual Health
(ISSWSH), as well as Past President of The North American Menopause
Society (NAMS), and
- James A. Simon. M.D., CCD, NCMP,
IF, FACOG, Clinical Professor, Obstetrics and Gynecology, George
Washington University and President and Medical Director of
IntimMedicine Specialists®, as well as Past President of each of
NAMS and ISSWSH.
A link to access the live webinar will be
available under “Presentations, Events & Webcasts" in the
Investors section of the Company's website at
http://ir.darebioscience.com. Following the conclusion of the live
event, a replay will be available under “Presentations, Events
& Webcasts" in the Investors section of the Company's website
at http://ir.darebioscience.com until September 1, 2023.
About FSAD and Sildenafil Cream,
3.6%
FSAD is a condition characterized primarily by a
persistent or recurrent inability to attain or maintain sufficient
genital arousal (an adequate lubrication-swelling response) during
sexual activity, frequently resulting in distress or interpersonal
difficulty, and, of the various types of female sexual dysfunction
disorders, FSAD is most analogous to erectile dysfunction (ED) in
men. As with ED in men, FSAD is associated with insufficient blood
flow to the genitalia.
Sildenafil, a phosphodiesterase-5 (PDE-5)
inhibitor, is the active ingredient in a tablet for oral
administration currently marketed under the brand name Viagra® for
the treatment of ED in men. Sildenafil Cream, 3.6% (Sildenafil
Cream) is an investigational, proprietary cream formulation of
sildenafil designed for topical administration to the
vulvar-vaginal tissue to increase genital blood flow and provide
improvements in the female genital arousal response, while avoiding
systemic side effects observed with oral formulations of
sildenafil. If development is successful, Sildenafil Cream has the
potential to be the first FDA-approved pharmacologic treatment for
FSAD.
Market research suggests that 16% of women in
the U.S. ages 21 to 60, or approximately 10 million women, are
distressed from experiencing symptoms associated with FSAD,
including lack of or low sexual arousal, and are actively seeking
solutions to improve their condition. In comparison, the prevalence
of complete ED in men is estimated to be about 5% of men at age 40,
increasing to about 15% at age 70.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company
committed to advancing innovative products for women’s health. The
company’s mission is to identify, develop and bring to market a
diverse portfolio of differentiated therapies that prioritize
women's health and well-being, expand treatment options, and
improve outcomes, primarily in the areas of contraception, vaginal
health, reproductive health, menopause, sexual health and
fertility.
Daré’s first FDA-approved product, XACIATO™
(clindamycin phosphate) vaginal gel, 2% is a lincosamide
antibacterial indicated for the treatment of bacterial vaginosis in
female patients 12 years of age and older, which is under a global
license agreement with Organon. XACIATO is a clear, colorless,
viscous gel, to be administered once intravaginally as a single
dose. Daré’s portfolio also includes potential first-in-category
candidates in clinical development: Ovaprene®, a novel,
hormone-free monthly intravaginal contraceptive whose U.S.
commercial rights are under a license agreement with Bayer;
Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to
treat female sexual arousal disorder utilizing the active
ingredient in Viagra®; and DARE-HRT1, a combination bio-identical
estradiol and progesterone intravaginal ring for menopausal hormone
therapy. To learn more about XACIATO, Daré’s full portfolio of
women’s health product candidates, and Daré’s mission to deliver
differentiated therapies for women, please visit
www.darebioscience.com.
Daré may announce material information about its
finances, product and product candidates, clinical trials and other
matters using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company, and may also use
social media to communicate important information about the
company, its finances, product and product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and
@DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted in
the Investors section of Daré’s website.
Contacts:
Investors on behalf of Daré Bioscience,
Inc.:Lee Roth / Julia WeilmanBurns
McClellanlroth@burnsmc.com / jweilman@burnsmc.com 646.930.4406
Media on behalf of Daré Bioscience, Inc.:Jake
RobisonEvoke Canalejake.robison@evokegroup.com 619.849.5383
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2024 to May 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From May 2023 to May 2024